BioSpace News Archive

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2022 financial results after market close on Monday, May 9, 2022.

Olema Pharmaceuticals, Inc. today announced that the Company granted a stock option to one new employee to purchase 20,000 shares of the Company’s common stock, effective as of April 1, 2022.

Repro Med Systems, Inc. today announced the appointment of Brian Case, a veteran medical technology R&D leader with over 20 years of experience, as the Company’s new Chief Technology Officer.

The American Society for Preventive Cardiology (ASPC) announces the official program for the ASPC 2022 Congress on CVD Prevention, scheduled July 29-31, 2022 in Louisville, KY.

Rising caseload of cancer across the globe, increasing investment to develop robust anti-cancer therapies, and growing need for tailored and customized therapeutic approaches for maximum effect are some key factors expected to drive market growth.

Technological advancements in DNA sequencing, improvement in healthcare infrastructure and research facilities, and increasing investments in research and development activities are key factors fueling global market growth.

Stemson Therapeutics Corp. announced that Paul Laikind, serial entrepreneur and former CEO of cell therapy company ViaCyte, has joined the Stemson Board of Directors.

Prostate cancer market is ready to develop at a dramatic speed, fundamentally because of the mounting pervasiveness of prostate malignant growth, quickly maturing populace and solid reinforcing pipeline.

OrthoPediatrics Corp. announced that the Company is scheduled to release its first quarter 2022 financial results on Wednesday, May 4, 2022, after the market closes.

DUBAI, United Arab Emirates, In 2022, the global market for a veterinary disinfectant for pets and farms is expected to be worth USD 3.2 billion.